ArticleCancer immunology, immunotherapy : CII2021
Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- MRI imaging features for predicting macrotrabecular-massive subtype hepatocellular carcinoma: a systematic review and meta-analysis.European radiology · 2024Pooled it
- Role of CMTM6 in disease pathogenesis and clinical translation potential (Review).Molecular medicine reports · 2026Review
- Preoperative Gd-EOB-DTPA-enhanced MRI may help predict macrotrabecular-massive subtype and postoperative recurrence in small hepatocellular carcinoma (≤ 3 cm).European radiology · 2026Article
- Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.European radiology · 2026Review
- Preoperative contrast-enhanced CT for predicting the macrotrabecular-massive subtype and its prognostic significance in hepatocellular carcinoma.Quantitative imaging in medicine and surgery · 2025Article
- Dynamic contrast-enhanced ultrasound perfusion analysis for preoperative prediction of aggressive hepatocellular carcinoma subtypes.Insights into imaging · 2025Article
- Macrotrabecular-massive subtype in hepatocellular carcinoma based on contrast-enhanced CT: deep learning outperforms machine learning.Insights into imaging · 2025Article
- Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Comprehensive analysis of CMTM family and immune infiltration in esophageal carcinoma.PloS one · 2025Article
- Preoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics.Journal of hepatocellular carcinoma · 2025Article
- A Comprehensive Pan-cancer Analysis Identified that TRIB3 was Associated with Immune Cell Infiltration and Poor Prognosis.Current pharmaceutical biotechnology · 2025Article
- A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors.Human vaccines & immunotherapeutics · 2024Article
- Article
- Nomogram based on CMTM6 expression and clinical characteristics to predict postoperative overall survival in patients with hepatocellular carcinoma.Histology and histopathology · 2024Article
- Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods.Heliyon · 2024Review
- Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications.Abdominal radiology (New York) · 2024Article
- Review
- Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function.British journal of pharmacology · 2024Review
- [Analysis of strong invasive clinical features and poor prognosis in macrotrabecular-massive hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The "macrotrabecular-massive" (MTM) pattern of hepatocellular carcinoma (HCC) has been suggested to represent a distinct HCC subtype and is associated with specific molecular features. Since the immune microenvironment is heterogenous in HCC, it is important to evaluate the immune microenvironment of this novel variant. CMTM6, a key regulator of PD-L1, is an important immunocheckpoint inhibitor. This study aimed to evaluate the prognostic effect of CMTM6/PD-L1 coexpression and its relationship with inflammatory cells in HCC. We analyzed 619 HCC patients and tumors were classified into MTM and non-MTM HCC subtypes. The expression levels of CMTM6 and PD-L1 in tumor and inflammatory cells were evaluated by immunohistochemistry. The density of inflammatory cells in the cancer cell nest was calculated. Tumoral PD-L1 expression and inflammatory cell density were higher in the MTM type than in the non-MTM type. CMTM6-high expression was significantly associated with shorter OS and DFS than CMTM6-low expression in the whole HCC patient population and the MTM HCC patient population. Moreover, MTM HCC patients with CMTM6/PD-L1 coexpression experienced a higher risk of HCC progression and death. In addition, CMTM6/PD-L1 coexpression was shown to be related to a high density of inflammatory cells. Notably, a new immune classification, based on CMTM6/PD-L1 coexpression and inflammatory cells, successfully stratified OS and DFS in MTM HCC. CMTM6/PD-L1 coexpression has an adverse effect on the prognosis of HCC patients, especially MTM HCC patients. Our study provides evidence for the combination of immune status assessment with anti-CMTM6 and anti-PD-L1 therapy in MTM HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.